Business Description
aap Implantate AG
ISIN : DE000A3H2101
Description
aap Implantate AG develops, manufactures, and markets trauma products for orthopedics. The company classifies its products that are Trauma and Others. The product line of the company consists of a plating system under the brand LOQTEQ, and cannulated screws. The company's projects such as antibacterial silver coating technology and magnesium-based implants. It develops a plating system for the Shoulder, Knee, Elbow, Wrist, and Ankle Joint. The company sells its product directly to hospitals, syndicates, and hospital groups with the help of distributors.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.36 | |||||
| Equity-to-Asset | 0.64 | |||||
| Debt-to-Equity | 0.27 | |||||
| Debt-to-EBITDA | -1.36 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -0.95 | |||||
| Beneish M-Score | -3.16 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -19.8 | |||||
| 3-Year EBITDA Growth Rate | 35.6 | |||||
| 3-Year EPS without NRI Growth Rate | 37.5 | |||||
| 3-Year FCF Growth Rate | 29.6 | |||||
| 3-Year Book Growth Rate | -25.8 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 13.72 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 32.42 | |||||
| 9-Day RSI | 40.18 | |||||
| 14-Day RSI | 44.03 | |||||
| 6-1 Month Momentum % | 66.18 | |||||
| 12-1 Month Momentum % | 43.95 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.12 | |||||
| Quick Ratio | 1.03 | |||||
| Cash Ratio | 0.28 | |||||
| Days Inventory | 923.89 | |||||
| Days Sales Outstanding | 70.22 | |||||
| Days Payable | 331.01 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -37.1 | |||||
| Shareholder Yield % | -16.03 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 81.45 | |||||
| Operating Margin % | -34.06 | |||||
| Net Margin % | -33.34 | |||||
| FCF Margin % | -22.81 | |||||
| ROE % | -32.25 | |||||
| ROA % | -20.14 | |||||
| ROIC % | -25.17 | |||||
| 3-Year ROIIC % | -445.96 | |||||
| ROC (Joel Greenblatt) % | -37.7 | |||||
| ROCE % | -26.06 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 0.86 | |||||
| PB Ratio | 1.01 | |||||
| Price-to-Tangible-Book | 1.19 | |||||
| EV-to-EBIT | -4.06 | |||||
| EV-to-EBITDA | -6.6 | |||||
| EV-to-Revenue | 1.34 | |||||
| EV-to-FCF | -5.88 | |||||
| Price-to-Median-PS-Value | 0.31 | |||||
| Price-to-Net-Current-Asset-Value | 5.84 | |||||
| Earnings Yield (Greenblatt) % | -24.63 | |||||
| FCF Yield % | -21.98 | |||||
| Forward Rate of Return (Yacktman) % | -12.88 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers